[{"AccountsPayableCurrent_0_Q2_USD":1295000.0,"PreferredStockSharesAuthorized_0_Q2_shares":33333.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"OtherSundryLiabilities_0_Q2_USD":495000.0,"OtherNoncashIncomeExpense_2_Q2_USD":76000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":0.0,"OtherLiabilitiesCurrent_0_Q2_USD":3876000.0,"OtherCostAndExpenseOperating_2_Q2_USD":0.0,"OtherCostAndExpenseOperating_1_Q2_USD":0.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":1000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":2938000.0,"OtherComprehensiveIncomeLossNetOfTax_2_Q2_USD":-2000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1_Q2_USD":1000.0,"OtherAssetsNoncurrent_0_Q2_USD":2237000.0,"OtherAssetsMiscellaneous_0_Q2_USD":0.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":1467000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":1941000.0,"OperatingIncomeLoss_2_Q2_USD":-36576000.0,"OperatingIncomeLoss_1_Q2_USD":-19506000.0,"NonoperatingIncomeExpense_2_Q2_USD":-365000.0,"NonoperatingIncomeExpense_1_Q2_USD":-169000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2_Q2_USD":-2000.0,"NetIncomeLoss_2_Q2_USD":-36941000.0,"ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_2_Q2_USD":12000000.0,"ProceedsFromStockPlans_2_Q2_USD":59000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":84398000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":92341000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q2_USD":988000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q2_USD":53553000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q2_USD":185000.0,"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0_Q2_USD":61706000.0,"StockholdersEquity_0_Q2_USD":61706000.0,"ShortTermInvestments_0_Q2_USD":0.0,"ShareBasedCompensation_1_Q2_USD":1000000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":144000.0,"ShareBasedCompensation_2_Q2_USD":1920000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":10213000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-2364948000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2_Q2_USD":18737000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1_Q2_USD":9293000.0,"RepaymentsOfLongTermDebt_2_Q2_USD":2667000.0,"ProvisionForDoubtfulAccounts_2_Q2_USD":0.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":439000.0,"ProfitLoss_2_Q2_USD":-36941000.0,"ProfitLoss_1_Q2_USD":-19675000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":17839000.0,"NetIncomeLoss_1_Q2_USD":-19675000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-34370000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":12000000.0,"CommonStockValue_0_Q2_USD":93000.0,"CommonStockSharesOutstanding_0_Q2_shares":93309923.0,"CommonStockSharesIssued_0_Q2_shares":93309923.0,"CommonStockSharesAuthorized_0_Q2_shares":266500000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"CommitmentsAndContingencies_0_Q2_USD":null,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":31487000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":71881000.0,"CashCashEquivalentsAndShortTermInvestments_0_Q2_USD":71881000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1_Q2_USD":-19674000.0,"CashAndCashEquivalentsFairValueDisclosure_0_Q2_USD":142000.0,"AssetsCurrent_0_Q2_USD":74819000.0,"Assets_0_Q2_USD":77495000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":72600000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":76200000.0,"AmortizationOfFinancingCostsAndDiscounts_2_Q2_USD":260000.0,"AmortizationOfFinancingCostsAndDiscounts_1_Q2_USD":130000.0,"AdditionalPaidInCapital_0_Q2_USD":2426561000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":0.0,"AccruedLiabilitiesCurrent_0_Q2_USD":8569000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":71881000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_Q2_USD":-36943000.0,"CostsAndExpenses_1_Q2_USD":19506000.0,"CostsAndExpenses_2_Q2_USD":36576000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":53857000.0,"LongTermDebtCurrent_0_Q2_USD":2049000.0,"LiabilitiesCurrent_0_Q2_USD":15789000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":77495000.0,"Liabilities_0_Q2_USD":15789000.0,"InvestmentIncomeNet_2_Q2_USD":19000.0,"InvestmentIncomeNet_1_Q2_USD":8000.0,"InterestPaidNet_2_Q2_USD":129000.0,"InterestExpense_2_Q2_USD":113000.0,"InterestExpense_1_Q2_USD":45000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":-494000.0,"IncreaseDecreaseInOperatingLiabilities_2_Q2_USD":-30000.0,"ForeignCurrencyTransactionGainLossBeforeTax_2_Q2_USD":-11000.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q2_USD":-2000.0,"EarningsPerShareDiluted_1_Q2_USD":-0.21,"EarningsPerShareDiluted_2_Q2_USD":-0.44,"EarningsPerShareBasic_2_Q2_USD":-0.44,"EarningsPerShareBasic_1_Q2_USD":-0.21,"DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_2_Q2_USD":0.0,"DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_1_Q2_USD":0.0,"DepreciationAndAmortization_2_Q2_USD":263000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":84398000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":92341000.0,"Ticker":"CTIC","CIK":"891293","name":"CTI BIOPHARMA CORP","OfficialName":"CTI BioPharma Corp. (DE) Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"472610380.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210805"}]